After achieving statistically significant efficacy endpoints in a second Phase III study, Avanir Pharmaceuticals Inc. said it anticipates seeking regulatory approval later this year for Neurodex in the treatment of pseudobulbar affect, a syndrome that occurs with a number of neurodegenerative diseases. (BioWorld Today)
After revealing favorable results from three multicenter clinical trials of modafinil in attention deficit hyperactivity disorder in children and adolescents, Cephalon Inc. said it expects to seek regulatory approval earlier than previously stated. (BioWorld Today)
After revealing favorable results from three multicenter clinical trials of modafinil in attention deficit hyperactivity disorder in children and adolescents, Cephalon Inc. said it expects to seek regulatory approval earlier than previously stated. (BioWorld Today)
